New results for risdiplam in spinal muscular atrophy
- PMID: 36244363
- DOI: 10.1016/S1474-4422(22)00427-6
New results for risdiplam in spinal muscular atrophy
Conflict of interest statement
SI receives partial salary support from NIH Wellstone Muscular Dystrophy Center (P50HD087351), NeuroNEXT (U24NS107176), and the Muscular Dystrophy Association. She receives research support from the DoD W81XWH2010293, Parent Project for MD, CureSMA and industry (Capricor, RegenXBio, Novartis, Biogen, Sarepta, PTC Therapeutics, Scholar Rock, FibroGen and ReveraGen). She has served on Medical Advisory Boards for Novartis, Biogen, and Sarepta and as a consultant for Genentech.
Comment on
-
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.Lancet Neurol. 2022 Dec;21(12):1110-1119. doi: 10.1016/S1474-4422(22)00339-8. Epub 2022 Oct 14. Lancet Neurol. 2022. PMID: 36244364 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical